Items where Author is "Herbst, R."

Article

Klespe, K. C. and Kochanek, C. and Schadendorf, D. and Ugurel, S. and Mohr, P. and Meier, F. and Weichenthal, M. and Pfoehler, C. and Haferkamp, S. and Herbst, R. and Terheyden, P. and Meiss, F. and Ulrich, J. and Utikal, J. S. and Leiter-Stoeppke, U. and Gutzmer, R. and von Wasielewski, I. (2023) Influence of BRAF mutation status on the effectiveness of immune checkpoint inhibition in metastatic melanoma - a multicenter study from the ADOREG. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 21. pp. 28-29. ISSN 1610-0379, 1610-0387

Gutzmer, R. and Ugurel, S. and Eigentler, T. and Mohr, P. and Weichenthal, M. and Gebhardt, C. and Goeppner, D. and Haferkamp, S. and Herbst, R. and Kaehler, K. C. and Kreuter, A. and Meier, F. and Pfoehler, C. and Sachse, M. M. and Herber, M. and Terheyden, P. and Ulrich, J. and Utikal, J. S. and von Wasielewski, I. and Schadendorf, D. (2023) Relationship between baseline health-related quality of life (HRQoL) measures and clinical outcomes of nivolumab (NIVO) or nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with unresectable or metastatic melanoma using real-world data from the non-interventional study (NIS) NICO in Germany. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 21. pp. 6-8. ISSN 1610-0379, 1610-0387

Gutzmer, R. and Schulze, H. -J. and Hauschild, A. and Leiter, U. and Meier, F. and Haferkamp, S. and Ulrich, C. and Wahl, R. U. and Berking, C. and Herbst, R. and Haeckl, M. and Schadendorf, D. (2021) Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real-world conditions in Germany - The non-interventional study NIELS. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 35 (8). pp. 1678-1685. ISSN 0926-9959, 1468-3083

Conference or Workshop Item

Franklin, C. and Mohr, P. and Meier, F. and Weichenthal, M. and Grimmel-Mann, I. and Gutzmer, R. and Utikal, J. S. and Terheyden, P. and Herbst, R. and Haferkamp, Sebastian and Pföhler, C. and Leiter-Stöppke, U. and Ziller, F. and Meiß, F. and Ulrich, J. and Kreuter, A. and Gebhardt, C. and Welzel, J. and Schilling, B. and Kaatz, M. and Scharfetter-Kochanek, K. and Dippel, E. and Nashan, D. and Sachse, M. M. and Weishaupt, C. and Löffler, H. and Gambichler, T. and Loquai, C. and Heinzerling, L. and Grabbe, S. and Debus, D. and Schley, G. and Weyandt, G. and Trommer, M. and Lodde, G. and Placke, J. M. and Zimmer, L. and Livingstone, E. and Horn, S. and Schadendorf, D. and Ugurel, S. (2022) FV20 Development of brain metastases and survival outcomes upon first-line systemic therapy in BRAF mutant and BRAF wildtype melanoma patients: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Kreft, S. and Glutsch, V. and Zaremba, A. and Schummer, P. and Mohr, P. and Grimmelmann, I. and Gutzmer, R. and Meier, F. and Pföhler, C. and Sachse, M. M. and Meiß, F. and Forschner, A. and Haferkamp, Sebastian and Welzel, J. and Terheyden, P. and Herbst, R. and Utikal, J. S. and Kaatz, M. and Weishaupt, C. and Kreuter, A. and Debus, D. and Dücker, P. and Sindrilaru, A. and Löffler, H. and Schley, G. and Weichenthal, M. and Schadendorf, D. and Ugurel, S. and Gesierich, A. and Schilling, B. (2022) eP001 MAPKinase Inhibition nach Versagen einer PD-1 basierten Immuncheckpoint Blockade in Patienten:innen mit fortgeschrittenem Melanom – eine Auswertung des multizentrischen prospektiven Hautkrebsregisters ADOREG. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Franklin, C. and Mohr, P. and Bluhm, L. and Grimmelmann, I. and Gutzmer, R. and Meier, F. and Garzarolli, M. and Weichenthal, M. and Herbst, R. and Pföhler, C. and Terheyden, P. and Utikal, J. S. and Ulrich, J. and Debus, D. and Haferkamp, Sebastian and Kaatz, M. and Forschner, A. and Leiter-Stöppke, U. and Nashan, D. and Kreuter, A. and Sachse, M. M. and Welzel, J. and Heinzerling, L. and Meiß, F. and Weishaupt, C. and Gambichler, T. and Weyandt, G. and Dippel, E. and Schatton, K. and Celik, E. and Trommer, M. and Helfrich, I. and Rösch, A. and Zimmer, L. and Livingstone, E. and Schaden-Dorf, D. and Horn, S. and Ugurel, S. (2022) eP003 Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Gilde, C. L. and Kochanek, C. and Zimmer, L. and Ugurel, S. and Meier, F. and Utikal, J. S. and Pföhler, C. and Herbst, R. and Haferkamp, Sebastian and Welzel, J. and Nashan, D. and Schadendorf, D. and Weichenthal, M. and Gutzmer, R. (2022) eP082 Auswirkung einer immunsuppressiven Therapie auf die Effizienz einer Therapieeinleitung mit Immuncheckpoint-Inhibitoren bei Patienten mit inoperabel metastasiertem Melanom – eine Auswertung des ADOreg. In: 32. Deutscher Hautkrebskongress (ADO-Jahrestagung), 14.–17. September 2022, Hannover.

Schadendorf, D. and Ugurel, S. and Eigentler, T. and Mohr, P. and Weichenthal, M. and Gebhardt, C. and Göppner, D. and Haferkamp, Sebastian and Herbst, R. and Kähler, K. and Kreuter, A. and Meier, F. and Pföhler, C. and Sachse, M. M. and Sickmann, T. and Terheyden, P. and Ulrich, J. and Utikal, J. S. and Grimmelmann, I. and Gutzmer, R. (2021) Age-dependent Efficacy and Safety of Nivolumab (NIVO) as Monotherapy or Combination Therapy with Ipilimumab (NIVO plus IPI) in Patients with advanced Melanoma in the non-interventional Study (NIS) NICO. In: 31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, hybrid.

Weichenthal, M. and Mohr, P. and Leiter-Stoeppke, U. and Ugurel, S. and Kaehler, K. and Gutzmer, R. and Pfoehler, C. and Hassel, J. C. and Nashan, D. and Terheyden, P. and Schell, B. and Utikal, J. S. and Kreuter, A. and Haferkamp, S. and Kaune, K. and Berking, C. and Debus, D. and Ulrich, J. and Dabrowski, E. and Eigentler, T. and Welzel, J. and Herbst, R. and Loquai, C. and Meier, F. and Schadendorf, D. (2021) The Effects of Brain Metastases in Melanoma Patients on anti-PD1 Antibody Therapy with Pembrolizumab. In: 31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, hybrid.

Gaiser, M. R. and Muüler, V. and Erdmann, M. and Bühler, B. and Dugas-Breit, S. and Schatton, K. and Reinhardt, L. and Mengoni, M. and Mickler, M. and Pföhler, C. and Weishaupt, C. and Herbst, R. and Debus, D. and Susok, L. and Tietze, J. K. and Welzel, J. and Arnold, A. and Dabrowski, E. and Forschner, A. and Goetze, S. and Hayani, K. and Lebbe, C. and Löhr, F. and Peitsch, W. K. and Poch, G. and Sachse, M. M. and Sindrilaru, A. and Wenk, S. and Ziemer, M. and Kaune, K. and Meier-Naust, L. and Nikolakis, G. and Oberndörfer, F. and Wesselmann, U. and Utikal, J. S. (2021) Melanoma in Pregnancy: CLAUDIUS - a retrospective, multicenter Study to evaluate the Risk of transplacental Transmission to the unborn Child. In: 31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, hybrid.

Haist, M. and Stege, H. and Mohr, P. and Meier, F. and Schadendorf, D. and Ugurel, S. and Livingstone, E. and Zimmer, L. and Herbst, R. and Pföhler, C. and Kähler, K. and Weichenthal, M. and Terheyden, P. and Nashan, D. and Debus, D. and Kaatz, M. and Ziller, F. and Haferkamp, S. and Forschner, A. and Leiter-Stöppke, U. and Kreuter, A. and Ulrich, J. and Kleemann, J. and Grabbe, S. and Loquai, C. (2021) Termination of targeted Therapy with BRAF-/MEK Inhibitors after an initial complete Response in Patients with metastatic Melanoma and its clinical Implications - a retrospective, multicenter ADOReg Study. In: 31. Deutscher Hautkrebskongress (ADO-Jahrestagung), 8.–11. September 2021, hybrid.

Other

Weichenthal, M. and Gutzmer, R. and Eigentler, T. and Mohr, P. and Goeppner, D. and Haferkamp, S. and Herber, M. and Herbst, R. and Meier, F. and Meiss, F. and Pfoehler, C. and Schneider, S. W. and Terheyden, P. and Ulrich, J. and Utikal, J. and Weishaupt, C. and Welzel, J. and Schadendorf, D. (2019) Real-world Data on advanced Melanoma: First Data from a national, prospective, non-interventional Study of Nivolumab in Combination with Ipilimumab or as Nivolumab Monotherapy (NICO). WILEY, HOBOKEN.

Roellig, C. and Serve, H. and Huettmann, A. and Noppeney, R. and Mueller-Tidow, C. and Krug, U. and Baldus, C. D. and Brandts, C. H. and Kunzmann, V and Einsele, H. and Kraemer, A. and Schaefer-Eckart, K. and Neubauer, A. and Burchert, A. and Giagounidis, A. and Krause, S. W. and Mackensen, A. and Aulitzky, W. and Herbst, R. and Haenel, M. and Kiani, A. and Frickhofen, N. and Kullmer, J. and Kaiser, U. and Link, H. and Geer, T. and Reichle, A. and Junghanss, C. and Bornhaeuser, M. and Schaich, M. and Thiede, C. and Schetelig, J. and Kramer, M. and Berdel, W. E. and Ehninger, G. (2018) The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival. Updated results from long-term follow-up of the randomized-controlled SORAML trial. KARGER, BASEL.

Heppt, M. and Heinzerling, L. and Kaehler, K. and Forschner, A. and Kirchberger, M. and Loquai, C. and Meissner, M. and Meier, F. and Terheyden, P. and Schell, B. and Herbst, R. and Goeppner, D. and Kiecker, F. and Rafei-Shamsabadi, D. and Haferkamp, S. and Huber, M. and Utikal, J. and Ziemer, M. and Bumeder, I and Pfeiffer, C. and Schd-Trcka, S. and Schmid-Tannwald, C. and Tietze, J. and Eigentler, T. and Berking, C. (2017) Prognostic factors and outcomes in metastatic uveal melanoma treated with PD-1 or combined PD-1 / CTLA-4 inhibition. WILEY, HOBOKEN.